Correction: MicroRNA expression in pre-treatment plasma of patients with benign breast diseases and breast cancer

Mirelle Lagendijk; Sepideh Saadatmand; Linetta B. Koppert; Madeleine M.A. Tilanus-Linthorst; Vanja de Weerd; Raquel Ramírez-Moreno; Marcel Smid; Anieta M. Sieuwerts; John W.M. Martens

doi:10.18632/oncotarget.25979

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: MicroRNA expression in pre-treatment plasma of patients with benign breast diseases and breast cancer

PDF | How to cite

Oncotarget. 2018; 9:32096-32096. https://doi.org/10.18632/oncotarget.25979

Metrics: PDF 2011 views | ?

Mirelle Lagendijk¹, Sepideh Saadatmand¹, Linetta B. Koppert¹, Madeleine M.A. Tilanus-Linthorst¹, Vanja de Weerd², Raquel Ramírez-Moreno², Marcel Smid², Anieta M. Sieuwerts^2,3 and John W.M. Martens^2,3

¹ Department of Surgical Oncology, Erasmus MC Cancer Institute, EA 3075, Rotterdam, The Netherlands
² Department of Medical Oncology, Erasmus MC Cancer Institute, EA 3075, Rotterdam, The Netherlands
³ Cancer Genomics Centre Netherlands, Erasmus University MC, CN 3015, Rotterdam, The Netherlands

Published: August 10, 2018

This article has been corrected: The correct author name is given below:

Sepideh Saadatmand

Original article: Oncotarget. 2018; 9:24335-24346. DOI: https://doi.org/10.18632/oncotarget.25262.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25979

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: MicroRNA expression in pre-treatment plasma of patients with benign breast diseases and breast cancer